ENTAHealthcare · BiotechnologyThe 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. hold a median 12-month price target of $20 — +79.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Enanta Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Revisions (31): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ENTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +79.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | JP Morgan | Initiates | Overweight | — |
| 1 Oct 2025 | Jefferies | Upgrade | Buy | — |
| 30 Sept 2025 | WestPark Capital | Maintains | Buy | — |
| 15 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 2 Sept 2025 | WestPark Capital | Initiates | Buy | — |
| 12 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 28 July 2025 | HC Wainwright & Co. | Assumes | Buy | $20 |
| 3 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 14 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 24 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Nov 2024 | Baird | Maintains | Outperform | — |
| 26 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 10 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ENTA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Enanta Pharmaceuticals, Inc. returned +4.9% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 23% of US stocks
Cheaper than 28% of US stocks
Cheaper than 83% of US stocks
Higher than 11% of US stocks
Higher than 13% of US stocks
Higher than 6% of US stocks
Higher than 17% of US stocks
Higher than 25% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enanta Pharmaceuticals, Inc. has a market value of $354.7M and an enterprise value of $347.3M.
Revenue in the twelve months to 30 June 2026: $65.3M. The latest quarter shrank 21.6% year on year.
Net income over the same four quarters: −$63.2M, a −96.9% net margin.
Diluted earnings per share, trailing twelve months: $−2.41.
Free cash flow in the twelve months to 30 June 2026: −$36.9M.
Trailing P/E: −3.0×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Enanta Pharmaceuticals, Inc. employs 120 people — $544K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Enanta Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Enanta said CEO and President Jay R. Luly will retire by February 1, 2027, after 23 years with the company. He will remain a strategic advisor through the remainder of 2027 to support the transition.
Why it matters — ENTA watchers may want to follow the leadership transition and its timing.
Enanta Pharmaceuticals announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 trial of zelicapavir in adults at high risk of severe outcomes from RSV. Topline data from the Phase 2b portion are expected in 2027.
Why it matters — The trial milestone advances Enanta’s clinical program for zelicapavir, a potential treatment for RSV.
Enanta Pharmaceuticals announced that data for zelicapavir, its oral, once-daily N-protein inhibitor in development for RSV, will be presented at IDWeek 2026, held October 21–24, both virtually and at the Walter E. Washington Convention Center.
Why it matters — The presentation will provide an opportunity for ENTA watchers to follow updates on a candidate being developed for RSV treatment.
Enanta Pharmaceuticals announced that members of its management will participate in two investor conferences in September: the Baird 2026 Global Healthcare Conference (fireside chat on September 15, 2026) and the H.C. Wainwright 28th Annual Global Investment Conference. The company is a clinical-stage biotechnology firm developing small molecule drugs for viral infections and immunological diseases.
Why it matters — Management's participation in these conferences gives ENTA watchers an opportunity to hear directly from company leadership about their clinical-stage programs.
Enanta Pharmaceuticals reported a fiscal-third-quarter loss of $0.67 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss but narrower than the $0.85 per share loss a year earlier.
Why it matters — The quarterly results missed analyst revenue and earnings expectations, which ENTA watchers would note as a sign of weaker-than-projected performance.
The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. have a median 12-month price target of $20, with estimates ranging from $19 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Enanta Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enanta Pharmaceuticals, Inc. 91 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Enanta Pharmaceuticals, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +79.4% from the last close, and Ticker Nerd's factor model ranks Enanta Pharmaceuticals, Inc. 91 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Enanta Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $32 over the next 12 months.
Enanta Pharmaceuticals, Inc. returned +4.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases.
The most recent item we track (Business Wire, 28 Oct 2026): "Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.". Enanta said CEO and President Jay R. Luly will retire by February 1, 2027, after 23 years with the company. He will remain a strategic advisor through the remainder of 2027 to support the transition.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.
CEO Dr. Jay R. Luly Ph.D. · 120 employees · United States · https://www.enanta.com
